Compare CETY & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CETY | CVKD |
|---|---|---|
| Founded | 1993 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Medicinal Chemicals and Botanical Products |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9M | 10.3M |
| IPO Year | 2020 | 2022 |
| Metric | CETY | CVKD |
|---|---|---|
| Price | $0.99 | $2.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 27.3K | ★ 71.1K |
| Earning Date | 05-19-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.94 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $957,633.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.18 | $2.29 |
| 52 Week High | $3.05 | $14.64 |
| Indicator | CETY | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 65.33 | 31.14 |
| Support Level | $0.71 | N/A |
| Resistance Level | $1.02 | $3.89 |
| Average True Range (ATR) | 0.08 | 0.42 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 92.56 | 6.56 |
Clean Energy Technologies Inc is clean energy and environmentally sustainable technologies company offering heat recovery solutions products. In addition, it also provides engineering and manufacturing solutions focused on other energy-efficient and environmentally sustainable technologies. The company's principal product is the Clean Cycle generator, offered by Heat Recovery Solutions. The company's engineering and manufacturing resources support its heat recovery solutions business. It has four segments: Clean Energy HRS & CETY Europe, CETY Renewables Waste to Energy Solutions, Engineering and Manufacturing Business and CETY HK. It serves various markets, including industrial, aerospace, military, instrumentation, and medical.
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.